Holen Sie sich die Stockscreener-App
18.09
0.95%
0.17
Handel nachbörslich:
17.80
-0.29
-1.60%
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
AMRX|Amneal Pharmaceuticals Inc|Price:17.920|Chg%:-0.050 - TradingKey
How Investors May Respond To Amneal Pharmaceuticals (AMRX) Expanding Its Iohexol Generic Portfolio Across OMNIPAQUE Formats - Sahm
ETFs Investing in Amneal Pharmaceuticals, Inc. Class A Stocks - TradingView
Amneal Pharmaceuticals Inc (AMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm - Business Wire
Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $19 - Moomoo
AMRX: Amneal Pharmaceuticals IncOrdinary SharesClass A Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism (AMRX) - Seeking Alpha
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals (AMRX) Proxy filing Summary - Quartr
How First-Generic OMNIPAQUE Rivals At Amneal Pharmaceuticals (AMRX) Have Changed Its Investment Story - Sahm
Amneal receives FDA approval for additional iohexol strengths By Investing.com - Investing.com South Africa
Amneal receives FDA approval for additional iohexol strengths - Investing.com
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations - The Manila Times
Amneal Pharmaceuticals Receives FDA Approval for Additional Iohexol Injection Strengths and Vial Presentations - Quiver Quantitative
Amneal's FDA-approved contrast options give hospitals more vial choices - Stock Titan
Amneal gains FDA approval for four iohexol products - grafa.com
Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD - Investing.com
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After Its Sharp Rerating? - Sahm
3 Reasons AMRX is Risky and 1 Stock to Buy Instead - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Barclays 28th Annual Global Healthcare Conference summary - Quartr
Amneal Pharmaceuticals stock holds steady as generic pipeline supports long term growth - Ad-hoc-news.de
Amneal schedules July 30 call for second-quarter 2026 results - Stock Titan
Amneal to Report Second Quarter 2026 Results on July 30, 2026 - The Manila Times
Amneals Planned Sterile Facility Creates Opportunity For Aseptic Filling Isolator And Automation Suppliers - Pharmaceutical Online
Enterprise value to revenue forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers - Yahoo Finance
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Kiely John - Moomoo
Amneal Sues Alembic to Block Copies of Crexont Parkinson’s Drug - Bloomberg Law News
Amneal Pharmaceuticals updates investors on its generics and specialty pipeline. The company focuses - ad-hoc-news.de
$2M from Amneal targets Parkinson's drug costs for patients - Stock Titan
Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced? - Sahm
Price to sales forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Amneal Pharmaceuticals : New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program - marketscreener.com
Price to book forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Price to earnings forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Sahm
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX) - Stock Titan
EMA Recommends Approval of Hopledo for Parkinson's Disease - Intellectia AI
Zambon and Amneal Receive Positive CHMP Opinion for Hopledo in Parkinson’s Disease in Europe - Quiver Quantitative
Zambon and Amneal Announce Positive CHMP Opinion for - GlobeNewswire
Does Amneal (AMRX) Joining Three Russell 2000 Defensive Indexes Recast Its Risk Profile? - simplywall.st
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS: AMRX) added to Russell 2000 Defensive Index - marketscreener.com
Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com UK
2DT Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX) - TradingView
AMRX Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals (AMRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com - Investing.com South Africa
0.30%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):